ArticleJournal of advanced research2021
Innate tumor-targeted nanozyme overcoming tumor hypoxia for cancer theranostic use.
Article in Journal of advanced research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 42 citations in OpenAlex.
- Manganese Ion-Based NanoPlatforms for Tumor Theranostics.Advanced healthcare materials · 2026Review
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
- Review
- TargetedImmunotherapy advances · 2026Review
- Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026Review
- Dual-magnetically driven nanozymes for glioblastoma immunotherapy via magnetothermal and NIR-amplified ferroptosis and apoptosis.Materials today. Bio · 2025Article
- Upregulated BAP31 Links to Poor Prognosis and Tumor Immune Microenvironment in Breast Cancer.International journal of molecular sciences · 2025Article
- Hypoxia-ameliorated photothermal manganese dioxide nanoplatform for reversing doxorubicin resistance.Frontiers in pharmacology · 2023Article
- Application Perspectives of Nanomedicine in Cancer Treatment.Frontiers in pharmacology · 2022Review
- BHLHE41 Overexpression Alleviates the Malignant Behavior of Colon Cancer Cells Induced by Hypoxia via Modulating HIF-1Gastroenterology research and practice · 2022Article
- Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis.Journal of nanobiotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypoxic tumor microenvironment (TME) is the major contributor to cancer metastasis, resistance to chemotherapy, and recurrence of tumors. So far, no approved treatment has been available to overcome tumor hypoxia.
objectivesThe present study aimed to relieve tumor hypoxia via a nanozyme theranostic nanomaterial as well as providing magnetic resonance imaging (MRI)-guided therapy.
methodsManganese dioxide (MnO
resultsBeing a TME-responsive nanomaterial, MnO
conclusionsMnO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.